Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33115
Full metadata record
DC FieldValueLanguage
dc.contributor.authorConduit, Ciara-
dc.contributor.authorLewin, Jeremy-
dc.contributor.authorWeickhardt, Andrew J-
dc.contributor.authorLynam, James-
dc.contributor.authorWong, Shirley-
dc.contributor.authorGrimison, Peter-
dc.contributor.authorSengupta, Shomik-
dc.contributor.authorPranavan, Ganes-
dc.contributor.authorParnis, Francis-
dc.contributor.authorBastick, Patricia-
dc.contributor.authorCampbell, David-
dc.contributor.authorHansen, Aaron R-
dc.contributor.authorLeonard, Matt-
dc.contributor.authorMcJannett, Margaret-
dc.contributor.authorStockler, Martin R-
dc.contributor.authorGibbs, Peter-
dc.contributor.authorToner, Guy-
dc.contributor.authorDavis, Ian D-
dc.contributor.authorTran, Ben-
dc.contributor.authorKuchel, Anna-
dc.date2023-
dc.date.accessioned2023-06-22T06:48:33Z-
dc.date.available2023-06-22T06:48:33Z-
dc.date.issued2023-11-
dc.identifier.citationJCO Oncology Practice 2023-11; 19(11)en_US
dc.identifier.issn2688-1535-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33115-
dc.description.abstractInternational guidelines advocate for active surveillance as the preferred treatment strategy for patients with stage 1 testicular cancer after orchidectomy although a personalized discussion is required. We conducted an analysis of individuals registered in iTestis, Australia's testicular cancer registry, to describe the patterns of relapse and outcomes of patients treated in Australia where the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations are widely adopted. A total of 650 individuals diagnosed between 2000 and 2020 were included, 63% (411 of 650) seminoma and 37% (239 of 650) nonseminoma. The median age was 34 years (range 14-74). 26% (106 of 411) with seminoma and 15% (36 of 239) nonseminoma received adjuvant chemotherapy. After a median follow-up of 43 months (range 0-267) postorchidectomy, relapse occurred in 10% (43 of 411) of seminoma and 18% (43 of 239) of nonseminoma. The two-year relapse-free survival was 92% (95% CI, 89 to 95) and 82% (95% CI, 78 to 87) in seminoma and nonseminoma, respectively. All relapses (86 of 86) were detected at a routine surveillance visit; 98% (85 of 86) were asymptomatic and detected solely through imaging (62 of 86, 72%), tumor markers (6 of 86, 7%), or a combination (17 of 86, 20%). The most common relapse site was isolated retroperitoneal lymphadenopathy (53 of 86, 62%). No nonpulmonary visceral metastases occurred. At relapse, 98% (84 of 86) had International Germ Cell Cancer Collaborative Group (IGCCCG) good prognosis; 2 of 86 intermediate prognosis (both nonseminoma). No deaths occurred. In our cohort of stage 1 testicular cancer, where national surveillance recommendations have been widely adopted, recurrences were detected at routine surveillance visits and, almost exclusively, asymptomatic with IGCCCG good-prognosis disease. This provides reassurance that active surveillance is safe.en_US
dc.language.isoeng-
dc.titlePatterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJCO Oncology Practiceen_US
dc.identifier.affiliationWalter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australiaen_US
dc.identifier.affiliationThe Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group, Camperdown, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Calvary Mater Newcastle, Waratah, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Western Health, Footscray, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Urology, Eastern Health, Box Hill, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Icon Cancer Centre, Adelaide, SA, Australia.en_US
dc.identifier.affiliationSouthside Cancer Care Centre, Kogarah, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Barwon Health, Geelong, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Princess Alexandra Hospital, Woolloongabba, QLD, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen_US
dc.identifier.affiliationUniversity of Newcastle, Callaghan, NSW, Australia.en_US
dc.identifier.affiliationNHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, St George/Sutherland Hospital, Caringbah, NSW, Australia.en_US
dc.identifier.affiliationUniversity of Sydney, Camperdown, NSW, Australia.en_US
dc.identifier.affiliationMonash University Eastern Health Clinical School, Box Hill, VIC, Australiaen_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, QLD, Australia.en_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australiaen_US
dc.identifier.affiliationONTrac at Peter Mac, Victorian Adolescent and Young Adult Cancer Service, Melbourne, VIC, Australia.en_US
dc.identifier.affiliationUniversity of Queensland, Brisbane, QLD, Australia.en_US
dc.identifier.affiliationLa Trobe University, Melbourne, VIC, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Concord Repatriation General Hospital, Concord, NSW, Australia.en_US
dc.identifier.affiliationDepartment of Medical Oncology, Eastern Health, Box Hill, VIC, Australia.en_US
dc.identifier.affiliationMedical Oncologyen_US
dc.identifier.doi10.1200/OP.23.00191en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-5258-4130en_US
dc.identifier.orcid0000-0002-4305-117Xen_US
dc.identifier.orcid0000-0002-6482-9681en_US
dc.identifier.orcid0000-0002-6742-820Xen_US
dc.identifier.orcid0000-0002-2653-1657en_US
dc.identifier.orcid0000-0003-3357-1216en_US
dc.identifier.orcid0000-0002-2363-8707en_US
dc.identifier.orcid0009-0000-1640-8068en_US
dc.identifier.orcid0000-0003-3793-8724en_US
dc.identifier.orcid0000-0003-1423-4484en_US
dc.identifier.orcid0000-0001-9873-3592en_US
dc.identifier.orcid0000-0002-9066-8244en_US
dc.identifier.orcid0000-0001-8580-2974en_US
dc.identifier.pubmedid37327464-
dc.description.startpageOP2300191-
local.name.researcherSengupta, Shomik-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptUrology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Jul 20, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.